title: Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
abstract: This retrospective study was undertaken to evaluate cure rates, toxicity and late effects of early intensive therapy followed by autologous stem cell transplantation (ASCT) in patients with advanced Hodgkin's disease (HD). One hundred and fifty-eight cases of ASCT registered in the French database (SFGM) were retrospectively analyzed. Disease status at the time of ASCT was first partial response (PR) in 85, first complete remission (CR1) in 45 or primary refractory in 28 cases. The median time interval between diagnosis and ASCT was 7 months (range 4-13). At the time of analysis in December 1995, 121/158 patients (76.6%) were alive, including 111 (70.2%) in continuous CR with a median follow-up for surviving patients of 46 months (range 8-123). Peri-ASCT toxic death rate was 3%, and the actuarial risk of new malignancies was 4.9% at 5 years. The cumulative probability of 5-year overall survival (OS) was 75.2% for the entire group of patients, 80.6% for the chemosensitive ones, and 33.9% for the primary refractory (chemosensitive vs refractory, P < 0.0001). The cumulative probability of 5-year event-free survival (EFS) was 66.1% for the entire group of patients, 73.7% for the chemosensitive ones, and 26.1% for the primary refractory (chemosensitive vs refractory, P < 0.0001). The only significant prognostic factor for both OS and EFS was disease status at the time of ASCT. Early ASCT in advanced HD is feasible, with a low risk of toxicity and without a higher rate of late effects compared with conventional treatment. Results achieved in chemosensitive patients at the time of transplantation lay the basis of future prospective randomized trials comparing ACST as front-line treatment to conventional treatment in high-risk cases.
authors.affiliation: Department of Hematology of Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: J
authors.initials: J
authors.lastname: Fleury
authors.forename: P
authors.initials: P
authors.lastname: Brice
authors.forename: P
authors.initials: P
authors.lastname: Colombat
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: B
authors.initials: B
authors.lastname: Lioure
authors.forename: L
authors.initials: L
authors.lastname: Voillat
authors.forename: O
authors.initials: O
authors.lastname: Casasnovas
authors.forename: S
authors.initials: S
authors.lastname: François
authors.forename: A
authors.initials: A
authors.lastname: Sadoun
authors.forename: T
authors.initials: T
authors.lastname: Lamy
authors.forename: J P
authors.initials: JP
authors.lastname: Lotz
authors.forename: J N
authors.initials: JN
authors.lastname: Munck
authors.forename: M
authors.initials: M
authors.lastname: Divine
authors.forename: C
authors.initials: C
authors.lastname: Fermé
authors.forename: A M
authors.initials: AM
authors.lastname: Pény
authors.forename: C
authors.initials: C
authors.lastname: Fruchart
authors.forename: P
authors.initials: P
authors.lastname: Oriol
authors.forename: M
authors.initials: M
authors.lastname: Ojeda
authors.forename: O
authors.initials: O
authors.lastname: Reman
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: M
authors.initials: M
authors.lastname: Legros
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous